Anthropic confirmed it has set up a wet lab in the San Francisco Bay Area, saying it is for physical biology work and not specifically for drug discovery, while declining to provide details about the lab’s size or biosafety level. The move was first reported by Reuters and confirmed by Eric Kauderer-Abrams, Anthropic’s head of life sciences. Anthropic said the lab supports its belief that “the final test” for biology is real lab work, while also noting that part of its biological work continues to be sent to external partners. The company also previously acquired Coefficient Bio for about $400 million in stock and has launched tools and partnerships tied to life sciences capabilities. For biotech and adjacent technology leaders, the lab announcement matters because it signals a more direct push into experimental execution rather than purely simulated pipelines. It also raises competitive questions about how AI-first companies integrate with wet-lab constraints like assay throughput, safety compliance, and experimentation timelines. Even with limited specifics, the wet-lab confirmation marks a concrete expansion of Anthropic’s life sciences footprint and adds another player to the ecosystem of AI-enabled biology experimentation.